Eli Lilly and Company (LLY)
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics. Zealand Pharma's weight management candidates, Survodutide and Petrelintide, show potential but face competition and valuation concerns, leading to a "hold" rating. Eli Lilly's revenue growth, driven by weight management treatments, and strategic moves like a $15 billion share buyback and dividend increase, indicate strong future prospects.
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake.
Eli Lilly's Alzheimer's treatment approved in China
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company said late on Tuesday.
15 Billion Reasons to Love Eli Lilly Stock Right Now
Pharmaceutical giant Eli Lilly (LLY 0.47%) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster diabetes and obesity care medications, Mounjaro and Zepbound.
Eli Lilly: A Rare Buying Opportunity
Eli Lilly's robust product portfolio, strategic acquisitions, and innovation-led initiatives drive its strong growth, positioning it well in the weight-loss, immunology, and oncology markets. LLY's key products, Mounjaro and Zepbound, dominate the U.S. weight-loss market, contributing significantly to revenue and long-term strategic advantages. My fair share price estimate of $1,164 indicates a 49% upside potential.
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious
As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (LLY 0.86%) is always providing investors with additional reasons to consider buying its stock.
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.
2 Weight Loss Stocks That Are Screaming Buys in December
With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines.
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
NVO's reiterated FY2024 guidance and underwhelming FY2025 guidance in "the high teens" imply growth headwinds after the high-double digit growth observed in FY2023. This may be worsened by the uncertain regulation surrounding "drug compounders and companies that sell their products," pending further clarity in 2025. Even so, we believe that FY2025 is likely to be trough year, with FY2026 bringing forth robust numbers, assuming regulatory approvals for CagriSema.
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its European rival.
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.
